Related Experiment Video
Updated: May 28, 2025
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
Published on: September 3, 2013
Targeting ADAR1 with a small molecule for the treatment of prostate cancer
Xiao Wang1,2,3, Jiaxing Li4,5, Yasheng Zhu4,5
1State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, China. xiaowang@cpu.edu.cn.
Abstract:
Despite the initial response to androgen signaling therapy, most cases of prostate cancer (PCa) eventually relapse and remain incurable. The specific function of ADAR1 that governs PCa progression and specific inhibitors of ADAR are underexplored. In this study, we demonstrate that highly expressed ADAR1 is a crucial oncogenic target in PCa and develop an effective small-molecule ADAR1 inhibitor, ZYS-1, with marked antitumor efficacy and a favorable safety profile. Either genetic or pharmacological inhibition of ADAR1 dramatically suppressed PCa growth and metastasis and potentiated the antitumor immune response. Moreover, ZYS-1 can enhance the antitumor effect of immunotherapy. We also reveal that ADAR1 represses the translation of MTDH in an editing-dependent manner, which drives cell proliferation and invasion in PCa. Collectively, our findings suggest that ADAR1 is a druggable target in PCa and highlight the widespread applicability of ADAR1 inhibitors for a broad spectrum of malignancies.
Insights
Most prostate cancers (PCa) relapse after treatment. This study identifies ADAR1 as a key driver of PCa and develops ZYS-1, an effective ADAR1 inhibitor with antitumor and immune-potentiating effects.
Area of Science:
- Oncology
- Molecular Biology
- Drug Development
Background:
- Prostate cancer (PCa) often relapses after androgen signaling therapy, leading to incurable disease.
- The role of ADAR1 in PCa progression and potential inhibitors are not well understood.
- Identifying novel therapeutic targets is crucial for overcoming treatment resistance in PCa.
Purpose of the Study:
- To investigate the oncogenic role of ADAR1 in prostate cancer progression.
- To develop and evaluate a novel small-molecule inhibitor of ADAR1.
- To explore the therapeutic potential of ADAR1 inhibition in PCa, including its effects on metastasis and immunotherapy.
Main Methods:
- Analysis of ADAR1 expression in PCa.
- Development of a small-molecule ADAR1 inhibitor (ZYS-1).
- In vitro and in vivo studies assessing the efficacy of ADAR1 inhibition on PCa growth, metastasis, and immune response.
- Investigation of the molecular mechanism involving ADAR1, MTDH translation, and PCa cell behavior.
Main Results:
- High ADAR1 expression is crucial for PCa progression and is a viable oncogenic target.
- The developed ADAR1 inhibitor, ZYS-1, demonstrated significant antitumor efficacy and a good safety profile.
- Inhibition of ADAR1 suppressed PCa growth and metastasis, and enhanced antitumor immunity.
- ZYS-1 potentiated the efficacy of immunotherapy in PCa models.
- ADAR1 was found to repress MTDH translation in an editing-dependent manner, promoting PCa cell proliferation and invasion.
Conclusions:
- ADAR1 is a druggable target for prostate cancer treatment.
- ADAR1 inhibition, particularly with ZYS-1, offers a promising therapeutic strategy for PCa.
- ADAR1 inhibitors may have broad applicability in treating various malignancies.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:22Alzheimer's Disease: Treatment